Ophthalmic Disease Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Anti-inflammatory, Anti-infectives, Anti-VEGF, Anti-glaucoma {Beta Blockers, Prostaglandins Analogs, Alpha Adrenergic Agonists}), By Dosage Form (Solid, Liquid, & Semisolid), By Disease Indication (Glaucoma {Open Angle Glaucoma, Angle Closure Glaucoma}, Dry Eye Disease, Retinal Diseases {Diabetic Macular Edema, Macular Degeneration}, Allergy & Infections), By Distribution Channel (Hospital Pharmacies and Retail & Online Pharmacies), & Regional Forecast, 2026-2034

ATTRIBUTE

DETAILS

Study Period

2021-2034

Base Year

2025

Estimated Year

2026

Forecast Period

2026-2034

Historical Period

2021-2024

Growth Rate

CAGR of 6.70% from 2026-2034

Unit

Value (USD billion)

Segmentation

By Drug Class

• Anti-inflammatory
• Anti-infectives
• Anti-VEGF
• Anti-glaucoma
  • Beta Blockers
  • Prostaglandins Analogs
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others
• Others

By Dosage Form

• Solid
• Liquid
• Semisolid

By Disease Indication

• Glaucoma
  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others
• Dry Eye Disease
• Retinal Diseases
  • Diabetic Macular Edema (DME)
  • Macular Degeneration (AMD)
  • Diabetic Retinopathy (DR)
  • Retinal Vein Occlusion (RVO)
  • Others
• Allergy & Infections
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail & Online Pharmacies

By Region

• North America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country)
  • U.S.
  • Canada
• Europe (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa